Current Report Filing (8-k)
February 27 2020 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 27, 2020
KRAIG
BIOCRAFT LABORATORIES, INC.
(Exact
name of registrant as specified in its charter)
Wyoming
|
|
333-164316
|
|
83-0458707
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
2723
South State St. Suite 150
Ann
Arbor, Michigan 48104
(Address of principal executive offices, including Zip Code)
(734)
619-8066
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
None
|
|
-
|
|
-
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (?230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01: Regulation FD Disclosure
On
February 27, 2020, Kraig Biocraft Laboratories, Inc. (the “Company”) issued a press release announcing a press
conference the Company will hold on March 19, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The
information reported under this Item 7.01 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed
to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference in such filing.
Item 8.01 Other Events.
To the extent required, the information
included in Item 7.01 of this Current Report on Form 8-K is incorporated in this Item 8.01 by reference.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
February 27, 2020
|
KRAIG
BIOCRAFT LABORATORIES, INC.
|
|
|
|
|
By:
|
/s/
Kim Thompson
|
|
|
Kim
Thompson
|
|
|
Chief
Executive Officer,
Chief Financial Officer and Director
|
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Apr 2023 to Apr 2024